SAR development of polycyclic guanine derivatives targeted to the discovery of a selective PDE5 inhibitor for treatment of erectile dysfunction

Bioorganic and Medicinal Chemistry Letters

Volumn 14, Issue 5, 2004, Pages 1291-1294

  Pissarnitski, Dmitri A ^a   Asberom, Theodros ^a   Boyle, Craig D ^a   Chackalamannil, Samuel ^a   Chintala, Madhu ^a   Clader, John W ^a   Greenlee, William J ^a   Hu, Yueqing ^a   Kurowski, Stanley ^a   Myers, Joyce ^a   Palamanda, Jairam ^a   Stamford, Andrew W ^a   Vemulapalli, Subbarao ^a   Wang, Yuguang ^a   Wang, Peng ^a   Wu, Ping ^a   Xu, Ruo ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GUANINE DERIVATIVE; PHOSPHODIESTERASE V INHIBITOR;

ARTICLE; DRUG DESIGN; DRUG IDENTIFICATION; DRUG POTENCY; ERECTILE DYSFUNCTION; IC 50; STRUCTURE ACTIVITY RELATION;

EID: 10744223708     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2003.12.027     Document Type: Article

References (14)

1. Corbin J.D., Francis S.H. J. Biol. Chem. 274:1999;13729.
2. Sildenafil is contraindicated for patients taking NO donors or organic nitrates because of a synergistic effect on blood pressure. However, there was no deducible evidence of an increase in the mortality rate among sildenafil users. Gresser U., Gleiter C.H. Eur. J. Med. Res. 7:2002;435.
3. Rotella D.P. Nature Reviews Drug Discovery. 1:2002;674.
4. Human PDEs were isolated and assayed as described previously: Wang P., Wu P., Myers J.G., Stamford A., Egan R.W., Billah M.M. Life Sci. 68:2001;1997. Recombinant human PDE1A3 was assayed at the final concentration of cAMP of 10 μM. Recombinant human PDE1A3 was assayed at the final concentration of cAMP of 10 μM. Recombinant human PDE4B2 was assayed at the final concentration of cAMP of 1 μM. Human PDE6 isolated from retina was assayed at the final concentration of cGMP of 0.5 μM. All assays were performed in the presence of 2% DMSO and 0.1% BSA.
5. Ahn H.-S., Bercovici A., Boykow G., Bronnenkant A., Chackalamannil S., Chow J., Cleven R., Cook J., Czarniecki M., Domalski C., Fawzi A., Green M., Guendes A., Ho G., Laudicina M., Lindo N., Ma K., Manna M., McKittrick B., Mirzai B., Nechuta T., Neustadt B., Puchalski C., Pula K., Silverman L., Smith E., Stamford A., Tedesco R.P., Tsai H., Tulshian D., Vaccaro H., Watkins R.W., Weng X., Witkowski J.T., Xia Y., Zhang H. J. Med. Chem. 40:1997;2196.
6. Lam P.Y.S., Clark C.G., Saubern S., Adams J., Winters M.P., Chan D.M.T., Combs A. Tetrahedron Lett. 39:1998;2941.
7. All new compounds were characterized by LCMS and NMR.
8. Toplis J.G. J. Med. Chem. 15:1972;1006.
9. Ho G.D., Silverman L., Bercovici A., Puchalski C., Tulshian D., Xia Y., Czarniecki M., Green M., Cleven R., Zhang H., Fawzi A. Bioorg. Med. Chem. Lett. 9:1999;7.
10. Mawson S.D., Weavers R.T. Tetrahedron Lett. 34:1993;3139.
11. Bunnage, M. E.; Mathias, J. P.; Street, S. D. A.; Wood, A. WO 9849166, Chem. Abstr. 1998, 129, 330741.
12. Rotella D.P., Sun Z., Zhu Y., Krupinski J., Pongrac R., Seliger L., Normandin D., Macor J.E. J. Med. Chem. 43:2000;1257.
13. Rotella D.P., Sun Z., Zhu Y., Krupinski J., Pongrac R., Seliger L., Normandin D., Macor J.E. J. Med. Chem. 43:2000;5037.
14. Bi Y., Stoy P., Adam L., He B., Krupinski J., Normandin D., Pongrac R., Seliger L., Watson A., Macor J.E. Bioorg. Med. Chem. Lett. 11:2001;2461.